EUVIMEDEuropean Health Evidence
Uhr 7/7Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

How Should We Treat Severe Malaria in the Setting of Artemisinin Partial Resistance?

Philip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John

The American Journal of Tropical Medicine and Hygiene · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT. Artemisinin partial resistance (ART-R) threatens the control of falciparum malaria, but its impact on the treatment of severe malaria has been unclear. Two recent studies in Uganda have considered associations between PfK13 mutations linked to ART-R and treatment outcomes in children hospitalized with complicated or severe malaria and treated with intravenous artesunate. Children infected with ART-R parasites experienced delayed parasite clearance compared to those infected with drug-sensitive parasites. However, clinical outcomes, including mortality, length of hospital stay, incidence of subsequent febrile illness, and incidence of readmission did not differ between children infected with ART-R or drug-sensitive parasites. Therefore, at present treatment with intravenous artesunate should remain the standard-of-care to treat severe malaria in sub-Saharan Africa, even in the setting of ART-R, although continued study of treatment efficacy is warranted.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Philip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John
Quelle
The American Journal of Tropical Medicine and Hygiene
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0002-9637, 1476-1645
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Philip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John (2026). How Should We Treat Severe Malaria in the Setting of Artemisinin Partial Resistance?. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.26-0514
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1